Issues related to plasma therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Monitored issues related to pharmacy benefit management.
2025 · 1st Quarter (Jan 1 - Mar 31)
CSL BEHRING LLC
Filed by THE NICKLES GROUP, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 21, 2025
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- THE NICKLES GROUP, LLC
- Client
- CSL BEHRING LLC
- Filing UUID
- fb28483a-f1e2-4021-8515-35a0b50e04b0
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Monitored issues related to medical supply chain and pharmacy benefit management. Monitored issues related to drug pricing.
H.R. 1990, the American Innovation and R&D Competitiveness Act, as it relates to the R&D tax credit. Monitored H.R. 591, Defending American Jobs & Investment Act and H.R. 2423, Unfair Tax Prevention Act, as they relate to taxation of foreign-based multinationals. Issues related to the 2025 extension of the Tax Cut and Jobs Act provisions impacting corporations and the Orphan Drug Tax Credit.
Literal federal measure citations: H.R. 1990, H.R. 591, H.R. 2423
Issues related to tariffs.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.